Case 1: Assessing Psychosocial Burden and Realistic Goals in a Patient with Alopecia Areata

"Case 1: Assessing Psychosocial Burden and Realistic Goals in a Patient with Alopecia Areata" follows a young man with patchy scalp loss and an approaching wedding as Dr. Ungar works through classification and counseling.

Dr. Ungar reads Case 1, a 33-year-old man with 45 percent scalp hair loss, including a coin-sized vertex patch, who has relapsed twice after partial regrowth over 14 months. He has no eyebrow, eyelash, or nail involvement and normal thyroid function. He is getting married in six months and has seen minimal improvement after four months of topical corticosteroids.

Dr. Ungar sees severe disease despite the 45 percent figure, which falls short of the trial definition. The psychosocial distress, possible rapid progression, and desire for fast regrowth all point toward systemic therapy. Because the approved options for severe disease are all JAK inhibitors, he would gather history on safety risk factors, though this patient appears healthy and low risk.

On classification, Dr. Ungar uses the alopecia areata scale. Scalp loss of 0 to 20 percent is mild, 20 to 50 percent is moderate, and 50 percent or more is severe. Eyebrow or eyelash involvement, rapid progression, lack of treatment response, or psychosocial burden upgrades a patient by one category. This man starts as moderate and is upgraded to severe.

Counseling must begin early, he stresses. Regrowth takes months rather than weeks, so a six-month deadline is short, even though some treatments could deliver regrowth in that window without any guarantee. Dr. Ungar also notes that the burden grows the longer regrowth takes and that a deadline adds another layer of stress. Even after full regrowth, many patients worry about future hair loss, so clinicians should plan for short-term, medium-term, and long-term psychosocial needs.

Our next episode, "JAK Inhibitors for Alopecia Areata: Selectivity and Pivotal Trial Efficacy," turns to how the three approved agents work and how their pivotal trials compare.